Price to Book Value Chart

View Price to Book Value for FATE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Price to Book Value Chart
Start Trial

Historical Price to Book Value Data

View and export this data back to 2013. Start Trial.
Date Value
August 21, 2026 1.772
August 20, 2026 1.863
August 19, 2026 2.015
August 18, 2026 1.947
August 17, 2026 1.993
August 14, 2026 1.955
August 13, 2026 1.917
August 12, 2026 2.069
August 11, 2026 2.084
August 10, 2026 2.099
August 07, 2026 2.130
August 06, 2026 1.894
August 05, 2026 1.977
August 04, 2026 1.955
August 03, 2026 1.901
July 31, 2026 1.863
July 30, 2026 1.909
July 29, 2026 1.795
July 28, 2026 1.764
July 27, 2026 1.848
July 24, 2026 1.833
July 23, 2026 1.917
July 22, 2026 1.962
July 21, 2026 2.152
July 20, 2026 2.126
Date Value
July 17, 2026 2.114
July 16, 2026 2.076
July 15, 2026 2.274
July 14, 2026 2.274
July 13, 2026 2.297
July 10, 2026 2.358
July 09, 2026 2.365
July 08, 2026 2.228
July 07, 2026 2.297
July 06, 2026 2.274
July 02, 2026 2.221
July 01, 2026 2.297
June 30, 2026 2.054
June 29, 2026 1.566
June 26, 2026 1.359
June 25, 2026 1.210
June 24, 2026 1.333
June 23, 2026 1.398
June 22, 2026 1.391
June 18, 2026 1.352
June 17, 2026 1.268
June 16, 2026 1.229
June 15, 2026 1.300
June 12, 2026 1.333
June 11, 2026 1.275

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
Agenus, Inc. --
Amgen, Inc. 20.53
Anika Therapeutics, Inc. 2.077
BioCryst Pharmaceuticals, Inc. --
Imunon, Inc. 1.787

Price to Book Value Related Metrics

PS Ratio 44.89
Price 2.435
Earnings Yield -43.24%
Market Cap 284.15M